A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Mengci Hu; Wenzhe Li; Pan Li; Jie Tan; Ya Wang

doi:10.3389/fonc.2024.1329279

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Front Oncol. 2024 Apr 26:14:1329279. doi: 10.3389/fonc.2024.1329279. eCollection 2024.

Authors

Mengci Hu^#¹, Wenzhe Li^#², Pan Li¹, Jie Tan¹, Ya Wang^{2

3}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
² Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
³ Department of Hubei Provincial Clinical Research Center for Personalized Diagnosis and Treatment of Cancer, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.

^# Contributed equally.

Abstract

Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.

Keywords: FLT3; acute lymphoblastic leukemia; diffuse large B-cell lymphoma; myelodysplastic syndrome; secondary acute lymphoblastic leukemia.

Publication types

Case Reports

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Grant from the Doctoral Research Initiation Fund Project of the First People's Hospital of Jingzhou (Grant No. 2023DIF02).